Empiric Quadruple vs. Triple Therapy for Primary Treatment ofHelicobacter pyloriInfection: Systematic Review and Meta-Analysis of Efficacy and Tolerability

J Luther, PDR Higgins, PS Schoenfeld… - Official journal of the …, 2010 - journals.lww.com
OBJECTIVES: Recent treatment guidelines recommend two first-line therapies
forHelicobacter pyloriinfection: proton pump inhibitor (PPI), bismuth, tetracycline, and …

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis

E Gene, X Calvet, R Azagra… - Alimentary pharmacology …, 2003 - Wiley Online Library
Background: Triple therapy (proton pump inhibitor, clarithromycin and amoxicillin or an
imidazole) is the first‐line treatment for Helicobacter pylori infection. However, the …

Meta‐analysis: Four‐Drug, Three‐Antibiotic, Non‐bismuth‐Containing “Concomitant Therapy” Versus Triple Therapy for Helicobacter pylori Eradication

AS Essa, JR Kramer, DY Graham, G Treiber - Helicobacter, 2009 - Wiley Online Library
Background: Low success rates with triple therapy for Helicobacter pylori infections have
prompted search for alternatives. In one, a proton‐pump inhibitor (PPI) and amoxicillin was …

Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment of Helicobacter pylori Infection

M Venerito, T Krieger, T Ecker, G Leandro… - Digestion, 2013 - karger.com
Background: In areas with high clarithromycin resistance, bismuth quadruple therapy (BQT)
is recommended instead of clarithromycin triple therapy (CTT) as the first-line treatment for …

Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies

LA Fischbach, SV Van Zanten… - Alimentary …, 2004 - Wiley Online Library
Background: Owing to rising drug‐resistant Helicobacter pylori infections, currently
recommended proton‐pump inhibitor‐based triple therapies are losing their efficacy, and …

Treatment of Helicobacter pylori infection: A clinical practice update.

RM Zagari, L Frazzoni, G Marasco, L Fuccio… - Minerva …, 2020 - europepmc.org
Helicobacter pylori infection still represents a major health issue, especially in developing
countries, with an estimate of 4 billion of infected subjects in 2015. The increase of antibiotic …

Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis

T Rokkas, JP Gisbert, P Malfertheiner, Y Niv… - Gastroenterology, 2021 - Elsevier
Background & Aims A number of double, triple, and quadruple therapies have been
proposed as first-line empiric treatments for Helicobacter pylori infection. However …

One‐week triple vs. quadruple therapy for Helicobacter pylori infection—a randomized trial

X Calvet, J Ducons, J Guardiola, L Tito… - Alimentary …, 2002 - Wiley Online Library
Background: Seven‐day triple therapy including omeprazole, clarithromycin and amoxicillin
has become the treatment of choice for Helicobacter pylori infection. However, 7 days of …

Clinical Outcomes of Two‐Week Sequential and Concomitant Therapies for Helicobacter pylori Eradication: A Randomized Pilot Study

JH Lim, DH Lee, C Choi, ST Lee, N Kim… - …, 2013 - Wiley Online Library
Background The eradication rate with PPI‐based standard triple therapy for Helicobacter
pylori infection has fallen considerably. One recent innovation is sequential therapy with PPI …

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori

JP Gisbert, X Calvet - Clinical and experimental gastroenterology, 2012 - Taylor & Francis
Background Traditional standard triple therapy for Helicobacter pylori (H. pylori) infection
(proton pump inhibitor-clarithromycin-amoxicillin) can easily be converted to non-bismuth …